Physician profile
Vincent Covelli
NPI 1528354347
$22,817.99
in general payments reported to CMS, 2019-2025
25 companies · $664 in 2025
The $664 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,510 · 2021: $1,089 · 2022: $747 · 2023: $6,023 · 2024: $838 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,410 · Food and Beverage: $2,717 · Travel and Lodging: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,410.00 |
| Food and Beverage | $2,716.77 |
| Travel and Lodging | $398.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17,298.86 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Allergan, INC. | $1,112.36 | 2019-2020 | |
| Boston Scientific Corporation | $998.62 | 2021-2025 | Accolade Sr, Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr |
| Gilead Sciences, INC. | $616.34 | 2019-2025 | Veklury, Yeztugo, Biktarvy |
| Viiv Healthcare Company | $565.86 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Janssen Biotech, INC. | $560.38 | 2021-2023 | Symtuza |
| Melinta Therapeutics, LLC | $331.11 | 2019-2024 | Kimyrsa, Rezzayo, Vabomere |
| Tetraphase Pharmaceuticals, INC. | $197.54 | 2019-2020 | |
| Abbvie INC. | $178.66 | 2020-2025 | |
| Janssen Products, LP | $161.77 | 2019-2023 | Symtuza |
| Shionogi INC | $129.26 | 2022-2024 | Fetroja |
| Janssen Scientific Affairs, LLC | $124.03 | 2023 | Symtuza |
| Astellas Pharma US INC | $113.49 | 2019 | |
| Pfizer INC. | $90.92 | 2025 | |
| Janssen Pharmaceuticals, INC | $81.54 | 2021-2024 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $56.06 | 2021-2025 | Brinsupri, Arikayce |
| Lilly USA, LLC | $40.48 | 2024 | Jardiance, Zepbound, Mounjaro |
| Solventum Corporation | $26.78 | 2025 | V.A.C.Ulta, V.A.C. Veraflo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.78 | 2023 | Jardiance |
| La Jolla Pharmaceutical Company | $22.26 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.07 | 2025 | Rebyota |
| Intercept Pharmaceuticals, INC. | $19.47 | 2020 | |
| Preventice Services, LLC | $17.34 | 2021 | |
| Baxter Healthcare | $14.56 | 2024 | Perclot |
| Novo Nordisk INC | $14.45 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Covelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.